Physician profile
Hani Horani
NPI 1437237542
$3,602.97
in general payments reported to CMS, 2019-2025
32 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $242 · 2021: $458 · 2022: $393 · 2023: $537 · 2024: $890 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $556.58 | 2021-2025 | Mounjaro, Kisunla, Zepbound |
| Abbvie INC. | $414.61 | 2021-2025 | |
| Novo Nordisk INC | $258.67 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.12 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $242.52 | 2019-2025 | |
| Abbott Laboratories | $239.70 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Exact Sciences Corporation | $210.67 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $206.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $186.29 | 2020-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $165.98 | 2019-2024 | Veozah |
| Eisai INC. | $126.38 | 2020-2024 | |
| Dexcom, INC. | $94.86 | 2023-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $73.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.23 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $66.32 | 2021-2023 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.83 | 2019-2025 | Evenity |
| Pfizer INC. | $49.42 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.11 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.65 | 2023 | Eliquis |
| Avanir Pharmaceuticals, INC. | $30.19 | 2019 | |
| Lundbeck LLC | $22.47 | 2023 | Rexulti |
| Verona Pharma, INC. | $22.43 | 2025 | Ohtuvayre |
| Lexicon Pharmaceuticals, INC. | $21.52 | 2024 | |
| Sanofi Pasteur INC. | $20.33 | 2023 | |
| Phathom Pharmaceuticals, INC. | $19.68 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $18.91 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.76 | 2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $18.05 | 2020 | |
| Neurocrine Biosciences, INC. | $16.79 | 2024 | Ingrezza |
| Harmony Biosciences LLC | $15.10 | 2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $14.79 | 2022 | |
| Merck Sharp & Dohme LLC | $14.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Horani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.